ReNeuron Group (RNUGF)
(Delayed Data from OTC)
$0.05 USD
+0.05 (4,490.91%)
Updated Apr 26, 2024 02:37 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
ReNeuron Group [RNUGF]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: ReNeuron Group
Industry: Medical - Drugs
H124 results reaffirm focus on CustomEXTM
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
H124 results reaffirm focus on CustomEXTM
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
H124 results reaffirm focus on CustomEXTM
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
A step forward for the Exosome delivery platform
Provider: Edison Investment Research Limited
Analyst: AATKAR A
Company: ReNeuron Group
Industry: Medical - Drugs
Company: ReNeuron Group
Industry: Medical - Drugs
Company: ReNeuron Group
Industry: Medical - Drugs
Encouraging data for iPSCs opens potential
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
Company: ReNeuron Group
Industry: Medical - Drugs
Rebranding in exosome targeted drug delivery -Re-initiation of coverage
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
Differentiating in exosome drug delivery
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: ReNeuron Group
Industry: Medical - Drugs
Company: ReNeuron Group
Industry: Medical - Drugs
Extension trial back on track but with data delay
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Short delay to hRP trial, data now likely in Q421
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Short delay to hRP trial, data now likely in Q421
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Continuing to gain clinical data in eye disease
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Funding to complete Phase IIa and other projects
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Exploiting the potential of cell therapy
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Strong data in retinal therapy shows long effects
Provider: Edison Investment Research Limited
Analyst: SAVIN J
Company: ReNeuron Group
Industry: Medical - Drugs
Focus on retinal therapy, out-licensing of stroke
Provider: Edison Investment Research Limited
Analyst: SAVIN J